Breakthrough In The Cancer Management

0
(Purdue University photo/Jared Pike)

A new device to test cancer drugs on multiple tumor cells to improve cancer management.

One of the biggest challenges in treating cancerous is to stop the uncontrolled growth and unregulated multiplication of the cancerous cells. Some of the chemotherapeutic agents have succeeded in slowing or stopping the rapid growth, but still, these agents fail; why?

Major components of pancreatic cancer progression are pancreatic stellate cells, which play a major role in the metastasis and drug resistance of the cancerous cells.

Since the cancer cells may quickly become resistant to these chemotherapeutic agents, here is where technology comes into play.

Researchers at Purdue University have designed a unique microfluidic device that can be used to test a cancer drug on multiple tumor cell subtypes. With the help of this device, the management of cancer can be revolutionized as new drug therapies can be discovered, and existing medicines can be used more effectively.

Bumsoo Han, one of the Purdue leads on the research, said:

“The drug discovery and screening process has been using one cancer cell subtype and studying how it interacts with neighboring non-cancer cells, but this may overestimate the efficacy of the drug. By condensing time to look at how cancer cells interact within a pancreatic tumor, we found that one cancer cell subtype can not only be more drug-resistant than the others, but drug-sensitive cells can also become resistant through interaction between the subtypes.”

The microfluidic device gets its name from its intricately designed collagen channels that mimic the pancreatic duct on a very small scale. The microfluidic device provides a platform for the cancerous cells to proliferate and grow, and the mucro collagen channels can receive the drug therapies which are to be tested on the malignant cells.

Although there have been similar devices in the past, all of those could work on the late-stage malignant cells. Microfluidic device has been designed with a step-up unique ability to detect the drug response in the earlier cell lines that have not yet mutated. This may help to find out which therapies are most effective at preventing mutations from happening.

SOURCEMedGadget
Previous articleFace Mask Sanitizes Exhaled Droplets
Next articleCase Of Five Finger Hands And PolyDactyly Of Feet
Dr. Arsia Hanif has been a meritorious Healthcare professional with a proven track record throughout her academic life securing first position in her MCAT examination and then, in 2017, she successfully completed her Bachelors of Medicine and Surgery from Dow University of Health Sciences. She has had the opportunity to apply her theoretical knowledge to the real-life scenarios, as a House Officer (HO) serving at Civil Hospital. Whilst working at the Civil Hospital, she discovered that nothing satisfies her more than helping other humans in need and since then has made a commitment to implement her expertise in the field of medicine to cure the sick and regain the state of health and well-being. Being a Doctor is exactly what you’d think it’s like. She is the colleague at work that everyone wants to know but nobody wants to be. If you want to get something done, you approach her – everyone knows that! She is currently studying with Medical Council of Canada and aspires to be a leading Neurologist someday. Alongside, she has taken up medical writing to exercise her skills of delivering comprehensible version of the otherwise difficult medical literature. Her breaks comprise either of swimming, volunteering services at a Medical Camp or spending time with family.

LEAVE A REPLY

Please enter your comment!
Please enter your name here